BR112019005930A2 - combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas - Google Patents

combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas

Info

Publication number
BR112019005930A2
BR112019005930A2 BR112019005930A BR112019005930A BR112019005930A2 BR 112019005930 A2 BR112019005930 A2 BR 112019005930A2 BR 112019005930 A BR112019005930 A BR 112019005930A BR 112019005930 A BR112019005930 A BR 112019005930A BR 112019005930 A2 BR112019005930 A2 BR 112019005930A2
Authority
BR
Brazil
Prior art keywords
inhibitor
vap
disorders
ssao
combinations
Prior art date
Application number
BR112019005930A
Other languages
English (en)
Inventor
Williams Mayoux Eric
Rippmann Joerg
Mark Michael
Klein Thomas
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112019005930A2 publication Critical patent/BR112019005930A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

a presente invenção refere-se a uma combinação farmacêutica de acordo com a invenção, compreendendo um inibidor de ssao/vap-1 de acordo com a fórmula (i) em que r1 a r6, e x são como definidos aqui, e um inibidor de sglt2. além disso, a presente invenção refere-se a métodos para prevenir, tornar mais lenta a progressão de, retardar ou tratar distúrbios fibróticos, distúrbios metabólicos, distúrbios de inflamação, doença oculares, distúrbios neuroinflamatórios ou câncer em um paciente em necessidade dos mesmos, caracterizados pelo fato de que a combinação farmacêutica de acordo com a invenção é administrada ao paciente.
BR112019005930A 2016-10-19 2017-10-16 combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas BR112019005930A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16194572 2016-10-19
PCT/EP2017/076300 WO2018073154A1 (en) 2016-10-19 2017-10-16 Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof

Publications (1)

Publication Number Publication Date
BR112019005930A2 true BR112019005930A2 (pt) 2019-06-11

Family

ID=57178303

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005930A BR112019005930A2 (pt) 2016-10-19 2017-10-16 combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas

Country Status (14)

Country Link
US (1) US20210212968A1 (pt)
EP (1) EP3528800A1 (pt)
JP (1) JP2019531320A (pt)
KR (1) KR20190070956A (pt)
CN (1) CN109843279A (pt)
AU (1) AU2017344882A1 (pt)
BR (1) BR112019005930A2 (pt)
CA (1) CA3041169A1 (pt)
CL (1) CL2019000935A1 (pt)
EA (1) EA201990951A1 (pt)
IL (1) IL265989A (pt)
MX (1) MX2019004549A (pt)
PH (1) PH12019500845A1 (pt)
WO (1) WO2018073154A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
US11787791B2 (en) 2018-09-28 2023-10-17 Acucela Inc. Inhibitors of VAP-1
JP2022511371A (ja) * 2018-09-28 2022-01-31 アキュセラ インコーポレイテッド Ｖａｐ－１の阻害剤
JP7414230B2 (ja) * 2018-11-09 2024-01-16 国立大学法人 琉球大学 抗血液悪性腫瘍薬
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 ***并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
BR112021010341A2 (pt) * 2018-12-14 2021-08-24 Yuhan Corporation 3,3-difluoroalilaminas ou sais das mesmas e composições farmacêuticas que compreendem as mesmas
CN114901649A (zh) 2019-10-29 2022-08-12 上海诚益生物科技有限公司 Ssao抑制剂及其用途
WO2021195435A1 (en) * 2020-03-25 2021-09-30 Terns, Inc. Treatment of respiratory disorders
EP4149453A1 (en) * 2020-05-13 2023-03-22 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN113893256A (zh) * 2020-07-06 2022-01-07 诺未科技（北京）有限公司 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用
AU2021332217A1 (en) 2020-08-25 2023-05-11 Eli Lilly And Company Polymorphs of an ssao inhibitor
WO2022183289A1 (en) * 2021-03-04 2022-09-09 The Governors Of The University Of Alberta The use of empagliflozin for the treatment of ulcerative colitis and crohn's disease
US20230241071A1 (en) * 2021-11-11 2023-08-03 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
WO2023086562A1 (en) * 2021-11-11 2023-05-19 Terns Pharmaceuticals, Inc. Treating liver disorders with an ssao inhibitor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE264337T1 (de) 1999-08-31 2004-04-15 Kissei Pharmaceutical Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
CA2429833A1 (en) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
PL209375B1 (pl) 2000-12-28 2011-08-31 Kissei Pharmaceutical Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej
PL210710B1 (pl) 2002-03-22 2012-02-29 Kissei Pharmaceutical Krystaliczne postaci 2-(4-metoksybenzylo) fenylo-6-O-etoksykarbonylo-ß-D-glukopiranozydu, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
MXPA05009356A (es) 2003-03-14 2005-12-05 Astellas Pharma Inc Derivados de c-glicosido y sales de los mismos.
EA015104B1 (ru) 2003-08-01 2011-06-30 Мицубиси Танабе Фарма Корпорейшн Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
RS52365B (en) 2004-03-16 2012-12-31 Boehringer Ingelheim International Gmbh BENZOL DERIVATIVES SUBSTITUTED BY GLUCOPYRANOSIL, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, THEIR USE AND THE PROCEDURE FOR THEIR PRODUCTION
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
EP2019679B1 (en) 2006-05-23 2018-06-20 Theracos, Inc. Glucose transport inhibitors and methods of use
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
US7846945B2 (en) 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
NZ582536A (en) 2007-07-26 2012-01-12 Lexicon Pharmaceuticals Inc Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
DK2200606T3 (en) 2007-09-10 2017-12-04 Janssen Pharmaceutica Nv PROCEDURE FOR THE PREPARATION OF RELATIONSHIP USED AS INHIBITORS OF SGLT
WO2009066152A2 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
TW201011043A (en) 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
AP2728A (en) 2008-08-28 2013-08-31 Pfizer Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
PT2395968T (pt) 2009-02-13 2024-03-05 Boehringer Ingelheim Int Composição farmacêutica compreendendo derivados de glucopiranosil difenilmetano, sua forma de dosagem farmacêutica, processo para a sua preparação e suas utilizações para controlo glicémico melhorado num doente
CN105343871A (zh) 2009-04-16 2016-02-24 大正制药株式会社 药物组合物
NZ598318A (en) 2009-09-30 2014-02-28 Boehringer Ingelheim Int Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
JP5758900B2 (ja) 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
ES2668300T3 (es) * 2012-05-02 2018-05-17 Boehringer Ingelheim International Gmbh Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos

Also Published As

Publication number Publication date
PH12019500845A1 (en) 2019-12-02
CA3041169A1 (en) 2018-04-26
AU2017344882A1 (en) 2019-03-28
EP3528800A1 (en) 2019-08-28
CN109843279A (zh) 2019-06-04
CL2019000935A1 (es) 2019-08-09
MX2019004549A (es) 2019-06-12
WO2018073154A1 (en) 2018-04-26
IL265989A (en) 2019-06-30
KR20190070956A (ko) 2019-06-21
JP2019531320A (ja) 2019-10-31
EA201990951A1 (ru) 2019-11-29
US20210212968A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
BR112019005930A2 (pt) combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112018000906A2 (pt) ?composto, medicamento, métodos de inibição da histona desacetilase em um mamífero, e para a profilaxia ou o tratamento de doenças, e, uso de um composto?
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
BR112017013022A2 (pt) métodos para tratar uma doença inflamatória e/ou autoimune aguda num mamífero que a necessite onde a terapia de corticosteróides é utilizada como terapia de primeira ou segunda linha e/ou para tratar uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção de primeira ou segunda linha e/ou para eliminar ou reduzir dose terapêutica de corticosteróides utilizado no tratamento de uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção crônica de primeira ou segunda linha e/ou de tratamento de uma doença autoimune e/ou inflamatória num mamífero que a necessite
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
BR112018006039A2 (pt) terapia adjuvante com 25-hidroxivitamina d e artigos para a mesma
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018003232A2 (pt) terapias de combinação para tratamento de câncer
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
TW201613578A (en) Pharmaceutical combinations
BR112017014924A2 (pt) Tratamento ou prevenção de caquexia induzida por cirurgia e/ou expressão de células supressoras de origem mieloide e citoquinas pró- inflamatórias
BR112015032029A2 (pt) uso de uma composição compreendendo óleo de peixe e suco para o tratamento de inflamação
WO2015035410A8 (en) Cancer therapy
BR112015019919A2 (pt) compostos bicíclicos
BR112017027897A2 (pt) usos terapêuticos das formulações de berberina
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
MX2016013611A (es) Uso del compuesto antigeno 4 del linfocito t toxico (ctla4) para lograr la remision libre de farmacos en sujetos con artritis reumatoide (ra) temprana.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2692 DE 09-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.